← Back to guidelines
Ophthalmology5 papers

Decompensated chronic heart failure

Last edited: 4/15/2026

Overview

Decompensated chronic heart failure (DHF) refers to a state where chronic heart failure progresses to manifest severe symptoms requiring urgent intervention, often due to impaired cardiac function leading to fluid retention and organ dysfunction 1.

Diagnosis

  • Clinical Symptoms: Dyspnea, fatigue, edema, and signs of systemic congestion 1.
  • Objective Measures: Elevated natriuretic peptides (BNP/NT-proBNP), jugular venous distension, rales on auscultation, peripheral edema 1.
  • Imaging: Echocardiography to assess ejection fraction, ventricular function, and presence of valvular disease 1.
  • Electrocardiogram (ECG): To rule out arrhythmias contributing to decompensation 1.
  • Management

  • Diuretics: Loop diuretics (e.g., furosemide) titrated to achieve decongestion, typically starting at 40 mg IV and adjusted based on response 1.
  • Vasopressors: Inotropic agents like dobutamine for hemodynamic support if hypotension is present 1.
  • Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Reception Blockers (ARBs): Continued use unless contraindicated, to reduce afterload and improve survival 1.
  • Beta-Blockers: Continued if tolerated, to improve long-term outcomes, though dose adjustments may be necessary 1.
  • Management of Complications: Address specific issues like arrhythmias, infection, or renal impairment 1.
  • Special Populations

  • Elderly: Careful titration of diuretics to avoid dehydration and electrolyte imbalances 1.
  • Comorbidities: Tailor management considering coexisting conditions like renal failure or liver disease, adjusting medications accordingly 1.
  • Key Recommendations

  • Initiate aggressive diuresis with loop diuretics to manage fluid overload, guided by clinical response and natriuretic peptide levels (Evidence: Moderate) 1.
  • Continuously monitor and adjust inotropic support as needed to maintain adequate perfusion pressure (Evidence: Moderate) 1.
  • Maintain guideline-directed medical therapy including ACE inhibitors/ARBs and beta-blockers unless contraindicated (Evidence: Strong) 1.
  • Individualize treatment for elderly patients focusing on minimizing adverse effects while managing congestion (Evidence: Expert opinion) 1.
  • Address and manage comorbid conditions to optimize overall patient outcomes (Evidence: Moderate) 1.
  • References

    1 Phillips PM, Phillips LJ, Much JW, Maloney C. Descemet stripping endothelial keratoplasty: six-month results of the first 100 consecutive surgeries performed solo by a surgeon using 1 technique with 100% follow-up. Cornea 2012. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG